Evidence mapPaperPMID 24696755Full record

ReviewHeart views : the official journal of the Gulf Heart Association2013

Contrast-induced Nephropathy.

Nazar M A Mohammed, Ahmed Mahfouz, Katafan Achkar, Ihsan M Rafie, Rachel Hajar

Registry-linked trialOpen access · diamondAbstract readReview
In one paragraph

Review in Heart views : the official journal of the Gulf Heart Association, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04375787 (High Dose Atorvastatin Raises Threshold of Contrast Induced Nephropathy in Diabetic Patients Undergoing Elective Coronary Intervention), which is not on this map. Cited by 96 papers, 8 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
96citing papers in PubMed, 8 pooled it
3.5field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04375787 phase4completedstarted 2020, after this paper: background citation

High Dose Atorvastatin Raises Threshold of Contrast Induced Nephropathy in Diabetic Patients Undergoing Elective Coronary Intervention

Ran2020Enrolled200Registered outcomes1Posted comparisons0ConditionsCoronary DiseaseArmsAtorvastatin
PMID 22714555PMID 21943940PMID 16949375other papers from this trial
Open the trial in the graph
3 · Its place in the literature

Who cites it

96 citing papers in PubMed, 8 syntheses or guidelines pooled it, 188 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Trial
  10. Trial
  11. Trial
  12. Trial
  13. Trial
  14. Trial
  15. Trial
  16. Trial
  17. Article
  18. Article
  19. Review
  20. Article

36 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Nazar M A MohammedDepartment of Cardiology, Heart Hospital, Hamad Medical Corporation, Doha, Qatar.
Ahmed MahfouzDepartment of Pharmacy, Heart Hospital, Hamad Medical Corporation, Doha, Qatar.
Katafan AchkarDepartment of Nephrology, Heart Hospital, Hamad Medical Corporation, Doha, Qatar.
Ihsan M RafieDepartment of Cardiology, Heart Hospital, Hamad Medical Corporation, Doha, Qatar.
Rachel HajarDepartment of Cardiology, Heart Hospital, Hamad Medical Corporation, Doha, Qatar.
Hamad Medical Corporation · QA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Contrast-induced nephropathy (CIN) is a serious complication of angiographic procedures resulting from the administration of contrast media (CM). It is the third most common cause of hospital acquired acute renal injury and represents about 12% of the cases. CIN is defined as an elevation of serum creatinine (Scr) of more than 25% or ≥0.5 mg/dl (44 μmol/l) from baseline within 48 h. More sensitive markers of renal injury are desired, therefore, several biomarkers of tubular injury are under evaluation. Multiple risk factors may contribute to the development of CIN; these factors are divided into patient- and procedure-related factors. Treatment of CIN is mainly supportive, consisting mainly of careful fluid and electrolyte management, although dialysis may be required in some cases. The available treatment option makes prevention the corner stone of management. This article will review the recent evidence concerning CIN incidence, diagnosis, and prevention strategies as well as its treatment and prognostic implications.

Indexed as

Contrast-induced nephropathydefinitionmanagement of contrast-induced nephropathyrisk scoring and stratifications

Identifiers

PMID24696755
PMCPMC3969626
OpenAlexW1976648341

What Socratic holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.